SCHEMBL257660

SCHEMBL257660

C=C(C)c1cc[nH]c1C(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.40
NR4A2 P43354 7/20 0.37
CREBBP Q92793 1/20 0.37
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.35
KDM4E B2RXH2 4/20 0.35
GAA P10253 2/20 0.35
GLA P06280 1/20 0.35
ALDH1A1 P00352 3/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PADI4 Q9UM07 1/20 0.35
KMT2A Q03164 1/20 0.35
PIM1 P11309 1/20 0.35
PIM3 Q86V86 1/20 0.35
CFTR P13569 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAP2K1 Q02750 1/20 0.34
POLB P06746 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8201374 0.85 CNR2 (0.42) CNR2NR4A2CREBBPTSHRLMNA
SCHEMBL69393 0.85 NR4A2 (0.44) CNR2NR4A2CREBBPTSHRLMNA
SCHEMBL27820698 0.81 CNR2 (0.42) CNR2NR4A2CREBBPTSHRLMNA
SCHEMBL28816343 0.76 ALDH1A1 (0.45) CNR2NR4A2CREBBPLMNAKDM4E
SCHEMBL27820699 0.76 NR4A2 (0.43) CNR2NR4A2CREBBPTSHRLMNA
SCHEMBL256714 0.73 CNR2 (0.44) CNR2NR4A2CREBBPTSHRLMNA
SCHEMBL2937272 0.73 CA12 (0.47) CNR2NR4A2CREBBPTSHRLMNA
SCHEMBL27906710 0.72 LMNA (0.42) CNR2NR4A2CREBBPTSHRLMNA
SCHEMBL24840712 0.72 CNR2 (0.43) CNR2NR4A2CREBBPTSHRLMNA
SCHEMBL13729391 0.72 CNR2 (0.43) CNR2NR4A2CREBBPTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024255697-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2024-12-19 WO disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 CNR2 285/4885NR4A2 547/4885CREBBP 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.